 |
|
Primary Prevention of Cardiovascular Diseases With Statin Therapy
A Meta-analysis of Randomized Controlled Trials
Paaladinesh Thavendiranathan, MD, MSc;
Akshay Bagai, MD;
M. Alan Brookhart, PhD;
Niteesh K. Choudhry, MD, PhD
Arch Intern Med. 2006;166:2307-2313.
Background While the role of hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) in secondary prevention of cardiovascular (CV) events and mortality is established, their value for primary prevention is less clear. To clarify the role of statins for patients without CV disease, we performed a meta-analysis of randomized controlled trials (RCTs).
Methods MEDLINE, EMBASE, Cochrane Collaboration, and American College of Physicians Journal Club databases were searched for RCTs published between 1966 and June 2005. We included RCTs with follow-up of 1 year or longer, more than 100 major CV events, and 80% or more of the population without CV disease. From each trial, demographic data, lipid profile, CV outcomes, mortality, and adverse outcomes were recorded. Summary relative risk (RR) ratios with 95% confidence intervals (CIs) were calculated using a random effects model.
Results Seven trials with 42 848 patients were included. Ninety percent had no history of CV disease. Mean follow-up was 4.3 years. Statin therapy reduced the RR of major coronary events, major cerebrovascular events, and revascularizations by 29.2% (95% CI, 16.7%-39.8%) (P<.001), 14.4% (95% CI, 2.8%-24.6%) (P = .02), and 33.8% (95% CI, 19.6%-45.5%) (P<.001), respectively. Statins produced a nonsignificant 22.6% RR reduction in coronary heart disease mortality (95% CI, 0.56-1.08) (P = .13). No significant reduction in overall mortality (RR, 0.92 [95% CI, 0.84-1.01]) (P = .09) or increases in cancer or levels of liver enzymes or creatine kinase were observed.
Conclusion In patients without CV disease, statin therapy decreases the incidence of major coronary and cerebrovascular events and revascularizations but not coronary heart disease or overall mortality.
Author Affiliations: Department of Medicine, University of Toronto, Toronto, Ontario (Drs Thavendiranathan and Bagai); and Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (Drs Brookhart and Choudhry).
RELATED LETTERS
The Role of Statins in Primary Prevention of Cardiovascular Disease
Klaus Eichler, Milo A. Puhan, and Lucas M. Bachmann
Arch Intern Med. 2007;167(10):1100.
EXTRACT
| FULL TEXT
The Role of Statins in Primary Prevention of Cardiovascular Disease—Reply
Paaladinesh Thavendiranathan, Akshay Bagai, M. Alan Brookhart, and Niteesh K. Choudhry
Arch Intern Med. 2007;167(10):1100-1101.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Preventing Heart Disease in the 21st Century: Implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study
McGill et al.
Circulation 2008;117:1216-1227.
FULL TEXT
Factors Related to Adherence to Statin Therapy
McGinnis et al.
The Annals of Pharmacotherapy 2007;41:1805-1811.
ABSTRACT
| FULL TEXT
Combined Effect of Low-Risk Dietary and Lifestyle Behaviors in Primary Prevention of Myocardial Infarction in Women
Akesson et al.
Arch Intern Med 2007;167:2122-2127.
ABSTRACT
| FULL TEXT
Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications
Tabas et al.
Circulation 2007;116:1832-1844.
ABSTRACT
| FULL TEXT
Statins and the Perioperative Period
Bronheim
SEMIN CARDIOTHORAC VASC ANESTH 2007;11:231-236.
ABSTRACT
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Afilalo et al.
Heart 2007;93:914-921.
ABSTRACT
| FULL TEXT
Adherence to Lipid-lowering Therapy and the Use of Preventive Health Services: An Investigation of the Healthy User Effect
Brookhart et al.
Am J Epidemiol 2007;166:348-354.
ABSTRACT
| FULL TEXT
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT
The Role of Statins in Primary Prevention of Cardiovascular Disease
Eichler et al.
Arch Intern Med 2007;167:1100-1100.
FULL TEXT
The Role of Statins in Primary Prevention of Cardiovascular Disease--Reply
Thavendiranathan et al.
Arch Intern Med 2007;167:1100-1101.
FULL TEXT
Evidently . . .
Lehman
Evid. Based Med. 2007;12:35-35.
FULL TEXT
Other articles noted
Evid. Based Med. 2007;12:63-64.
FULL TEXT
Primary Prevention of Atherosclerotic Cardiovascular Disease: The High Public Burden of Low Individual Risk
Lauer
JAMA 2007;297:1376-1378.
FULL TEXT
How Broadly Do Statin Benefits Extend?
Journal Watch Cardiology 2006;2006:4-4.
FULL TEXT
|
